Journal of Cancer Research and Therapeutics Close
 

Figure 2: A 57-year-old woman who underwent baseline and post-neoadjuvant PET/CT for a pathologically proven esophageal squamous cellular cancer with T3N0M0 (stage II) disease. At baseline PET/CT, an intense FDG-uptake was showed at the cervical esophagus with a SUVmax of 25.76 and a TLG of 249.71. The patient underwent combined neoadjuvant therapy (cisfolates and radiotherapy). PET/CT after treatment showed a less intense uptake of FDG in the same site with a SUVmax of 7 and a TLG of 18. Therefore, the change in SUVmax was 73% and in TLG was 93%. After 3 weeks from the second PET/CT, the patient was sent to a defi nitive surgery demonstrating a fi nal stage II (no response to combined neoadjuvant chemotherapy). The patient passed away after 15 months from the second PET/CT scan for a disseminate disease

Figure 2: A 57-year-old woman who underwent baseline and post-neoadjuvant PET/CT for a pathologically proven esophageal squamous cellular cancer with T3N0M0 (stage II) disease. At baseline PET/CT, an intense FDG-uptake was showed at the cervical esophagus with a SUVmax of 25.76 and a TLG of 249.71. The patient underwent combined neoadjuvant therapy (cisfolates and radiotherapy). PET/CT after treatment showed a less intense uptake of FDG in the same site with a SUVmax of 7 and a TLG of 18. Therefore, the change in SUVmax was 73% and in TLG was 93%. After 3 weeks from the second PET/CT, the patient was sent to a defi nitive surgery demonstrating a fi nal stage II (no response to combined neoadjuvant chemotherapy). The patient passed away after 15 months from the second PET/CT scan for a disseminate disease